$74 Billion Merger

In a federal class action, shareholders say directors are selling Celgene Corp. too cheaply through an unfair process to Bristol-Myers Squibb, for $50 a share plus a 1-for-1 share swap, a $74 billion merger.

WILMINGTON, Del. — In a federal class action, shareholders say directors are selling Celgene Corp. too cheaply through an unfair process to Bristol-Myers Squibb, for $50 a share plus a 1-for-1 share swap, a $74 billion merger. Bristol-Myers Squibb is not a party to the complaint.

Categories / Business, Health, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

﻿$74 Billion Merger

Subscribe to Closing Arguments

Additional Reads

$74 Billion Merger